Under construction – not a live service
Sign in
Taking people in FranceNo phase

Checks how many people with cystic fibrosis smoke or vape

Surveys adults with cystic fibrosis about smoking and vaping, including exposure to others' smoke.

Plain-language title generated from the registry record
Registry title: Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis

Key facts

Where
Strasbourg, FranceSee the site

Where in France

  • Service de Pneumologie - CHU de Strasbourg - FranceStrasbourg, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Hospital, Strasbourg, France
Trial code
NCT07342920
Record updated
15 January 2026
Original description
In the collective unconscious, a patient with cystic fibrosis does not smoke. This belief is so deeply rooted that there is virtually no French data on the prevalence of smoking among this vulnerable population.Read full original descriptionShow less

Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis

In the collective unconscious, a patient with cystic fibrosis does not smoke. This belief is so deeply rooted that there is virtually no French data on the prevalence of smoking among this vulnerable population.

Faced with a cohort of patients undergoing a complete transformation (improved quality of life and life expectancy, fewer hospitalizations, reduced respiratory symptoms, better social integration), it is becoming urgent to assess the current situation in order to optimize tobacco prevention.

This is all the more important given the emergence of international studies objectively examining the interactions between smoking, vaping, and the efficacy of Kaftrio.

Inclusion: Adult patient (≥ 18 years old); With confirmed cystic fibrosis; Regular follow-up at the Strasbourg Adult Cystic Fibrosis Center.

Exclusion: Patients who have undergone a double lung transplant for cystic fibrosis.

ClinicalTrials.gov NCT07342920